An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

• Status: Completed
• Trial end date: 2019-06-20
• Target enrollment: 0
• Participant gender: All

Summary

28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Spyryx Biosciences, Inc.
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Confirmed diagnosis of cystic fibrosis

• ppFEV1 (percent predicted FEV1) between 50.0% and 80.0%

• Stable CF Lung Disease

• Males and non-pregnant, non-lactating females

Exclusion Criteria:

• Significant unstable co-morbidities within 28 days of screening

• Has received an investigational drug within 28 days of screening